Colonoscopy

NEC Releases 'WISE VISION Endoscopy' in Europe and Japan

Tuesday, January 12, 2021 - 1:56am

TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.

Key Points: 
  • TOKYO, Jan 12, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the development of "WISE VISION Endoscopy," an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.
  • This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures.
  • Colorectal cancer is the most common cancer in Japan(1), and the second most common in Europe(2).
  • NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue.

NEC Releases “WISE VISION Endoscopy” in Europe and Japan

Tuesday, January 12, 2021 - 1:00am

NEC Corporation (NEC; TOKYO: 6701) today announced the development of WISE VISION Endoscopy, an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.

Key Points: 
  • NEC Corporation (NEC; TOKYO: 6701) today announced the development of WISE VISION Endoscopy, an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan today and is expected to soon be available in Europe.
  • This software connects with existing endoscopy equipment as part of using AI to automatically mark potential lesions from images taken during endoscopic procedures.
  • View the full release here: https://www.businesswire.com/news/home/20210111006087/en/
    Colorectal cancer is the most common cancer in Japan (*1), and the second most common in Europe (*2).
  • NEC has been working with the National Cancer Center Japan since 2016 to contribute to resolving this issue.

Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the Pure-Vu® System’s Universal Method to Mount on the End of Most Commercial Colonoscopes

Monday, January 11, 2021 - 12:45pm

The commercial potential of our system is more apparent than ever as our U.S. sales program continues to successfully build awareness for the Pure-Vu System among leading U.S. gastroenterologists and hospital systems.

Key Points: 
  • The commercial potential of our system is more apparent than ever as our U.S. sales program continues to successfully build awareness for the Pure-Vu System among leading U.S. gastroenterologists and hospital systems.
  • The United States Patent Office issued patent 10,881,277, which is titled Distal Front End for Coordinated Portioning of an Endoscope with Suction Device.
  • Motus GI estimates that approximately four million inpatient colonoscopy procedures take place worldwide each year.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOLVD Health Prepares to Launch Clinical Study of Non-Invasive Colorectal Cancer Screening Test

Wednesday, January 6, 2021 - 7:00pm

CARLSBAD, Calif., Jan. 6, 2021 /PRNewswire/ -- SOLVD Health ( www.solvdhealth.com ), a privately held company focused on preventing disease by making actionable and contextual health information accessible to everyone, is preparing to launch a U.S. clinical study of its non-invasive colorectal cancer (CRC) screening test, LifeKit Prevent.

Key Points: 
  • CARLSBAD, Calif., Jan. 6, 2021 /PRNewswire/ -- SOLVD Health ( www.solvdhealth.com ), a privately held company focused on preventing disease by making actionable and contextual health information accessible to everyone, is preparing to launch a U.S. clinical study of its non-invasive colorectal cancer (CRC) screening test, LifeKit Prevent.
  • "Colonoscopy is the current gold standard for colorectal cancer screening because it accurately detects cancer as well as precancerous adenomas," said Keri Donaldson , MD, CEO of SOLVD Health.
  • Early research has shown that our test is effective at detecting both, which could be a gamechanger for colorectal cancer screening."
  • SOLVD Health's prospective clinical trial will enroll up to 12,000 individuals to validate its test for the detection of colorectal cancer and adenomas.

Motus GI Announces Clinical Compendium of Pure-Vu System Patient Case Studies As Reported by Several Leading U.S. Hospitals

Wednesday, December 16, 2020 - 1:00pm

The case studies are now available on the Motus GI website ( click here ).

Key Points: 
  • The case studies are now available on the Motus GI website ( click here ).
  • One of the biggest takeaways from this collection of case studies is the variety of use cases where patients were unable to properly prep for a colonoscopy.
  • For example, in one study the patient had a long history of incomplete colonoscopies due to inadequate bowel prep.
  • Due to the Pure-Vu System, it was possible to directly visualize the entire colon which had been a challenge in the past.

Capital Digestive Care Offers Same-Day Colonoscopy Prep with New HyGieaCare® Center in Rockville, MD

Wednesday, December 9, 2020 - 11:30am

Capital Digestive Care is pleased to announce the opening of a new HyGieaCare Center in Rockville, MD.

Key Points: 
  • Capital Digestive Care is pleased to announce the opening of a new HyGieaCare Center in Rockville, MD.
  • With the HyGieaCare Prep System, patients can experience safe and easy bowel prep on the same day as their scheduled colonoscopy.
  • More than 15,000 patients across the country have chosen HyGieaCare for their colonoscopy prep with excellent clinical results and a 96% patient satisfaction rate.
  • The Capital Digestive Care HyGieaCare Center is currently scheduling patients.

EndoVigilant starts Pivotal Clinical Study to demonstrate Artificial Intelligence enabled assistance to gastroenterologists for detection of polyps during Colonoscopy

Monday, November 30, 2020 - 1:00pm

The first application focuses on real-time computer aided detection (CADe) assistance for improving polyp detection during colonoscopies.

Key Points: 
  • The first application focuses on real-time computer aided detection (CADe) assistance for improving polyp detection during colonoscopies.
  • Even though approximately 18 million colonoscopy procedures are performed annually in the US, adenomatous polyp miss rate as high as 26% often results in missed cancers.
  • Earlier this year, EndoVigilant reached an agreement with the FDA on the design of its pivotal clinical study.
  • "The progress of clinical pivotal study highlights our commitment to demonstrate the clinical benefits of EndoVigilant's CADe application and getting it in the hands of gastroenterologists as soon as possible," stated Vineet Sachdev, CEO and Co-Founder of EndoVigilant.

Geneoscopy Announces Positive Results of Colorectal Cancer Screening Test in Prospective, Multicenter Clinical Study

Thursday, November 19, 2020 - 6:03pm

Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced positive results of their diagnostic in detecting both colorectal cancer and precancerous adenomas in a large, multicenter prospective study.

Key Points: 
  • Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced positive results of their diagnostic in detecting both colorectal cancer and precancerous adenomas in a large, multicenter prospective study.
  • In particular, the observed detection rate of advanced adenomas offers novel capabilities for preventing the development of colorectal cancer, the second deadliest cancer in the United States.
  • The prospective, multicenter clinical study used digital platforms to virtually recruit and enroll 1,305 participants who provided a stool sample to Geneoscopy prior to receiving a screening colonoscopy.
  • To supplement the prospective cohort, Geneoscopy also assessed a retrospective cohort of patients previously diagnosed with colorectal cancer.

Sebela Pharmaceuticals Receives FDA Approval for SUTAB® Tablets for Colonoscopy Preparation

Tuesday, November 10, 2020 - 10:05pm

BRAINTREE, Mass., Nov. 10, 2020 /PRNewswire/ -- Sebela Pharmaceuticalstoday announces that the U.S. Food and Drug Administration (FDA) approved SUTAB (sodium sulfate, magnesium sulfate, and potassium chloride) tablets.

Key Points: 
  • BRAINTREE, Mass., Nov. 10, 2020 /PRNewswire/ -- Sebela Pharmaceuticalstoday announces that the U.S. Food and Drug Administration (FDA) approved SUTAB (sodium sulfate, magnesium sulfate, and potassium chloride) tablets.
  • Alan Cooke, President and CEO of Sebela Pharmaceuticals, said, "Gastroenterologists and their patients have repeatedly asked for a safe and efficacious tablet bowel prep.
  • SUTAB (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.
  • Administration of two doses of SUTAB (24 tablets) are required for a complete preparation for colonoscopy.

Motus GI and NYU Langone Health Partner to Improve its Inpatient Colonoscopy Management

Tuesday, November 3, 2020 - 1:00pm

FORT LAUDERDALE, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improve clinical outcomes, is launching a new clinical protocol with NYU Langone Health to incorporate the Companys Pure-Vu GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies.

Key Points: 
  • FORT LAUDERDALE, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improve clinical outcomes, is launching a new clinical protocol with NYU Langone Health to incorporate the Companys Pure-Vu GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies.
  • Seth Gross, MD, Director of Clinical Care and Quality in the Division of Gastroenterology at NYU Langone Health, has worked closely with Motus GI on the development of this protocol at NYU Langone Health, and will work with Motus GI to provide training and support for use of the Pure-Vu System.
  • Suboptimal bowel preparation can lead to missed diagnosis and extend exam time for inpatient GI procedures, Dr.
  • Within the last year, the Company initiated its commercial launch of the Pure-Vu System in the U.S. with an initial focus on inpatient colonoscopy.